Annual CFF
N/A
December 1, 2024
Summary
- ABBV annual cash flow from financing activities is not available.
Performance
ABBV Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFF
N/A
December 1, 2024
Summary
- ABBV quarterly cash flow from financing activities is not available.
Performance
ABBV Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFF
N/A
December 1, 2024
Summary
- ABBV TTM cash flow from financing activities is not available.
Performance
ABBV TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ABBV Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | - | - | - |
| 5 y5 years | - | - | - |
ABBV Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time |
AbbVie Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3.07 B(-49.6%) | -$2.80 B(+17.2%) |
| Jun 2024 | - | -$6.10 B(-156.4%) | -$2.39 B(+1031.8%) |
| Mar 2024 | - | $10.82 B(-343.2%) | -$211.00 M(-98.8%) |
| Dec 2023 | -$17.22 B(-30.6%) | -$4.45 B(+67.2%) | -$17.22 B(-23.1%) |
| Sep 2023 | - | -$2.66 B(-32.1%) | -$22.41 B(-11.3%) |
| Jun 2023 | - | -$3.92 B(-36.7%) | -$25.26 B(+5.2%) |
| Mar 2023 | - | -$6.19 B(-35.7%) | -$24.02 B(-3.1%) |
| Dec 2022 | -$24.80 B(+30.3%) | -$9.63 B(+74.6%) | -$24.80 B(+15.3%) |
| Sep 2022 | - | -$5.52 B(+106.0%) | -$21.51 B(+9.6%) |
| Jun 2022 | - | -$2.68 B(-61.6%) | -$19.63 B(-14.0%) |
| Mar 2022 | - | -$6.97 B(+10.0%) | -$22.84 B(+19.9%) |
| Dec 2021 | -$19.04 B(+65.5%) | -$6.34 B(+74.0%) | -$19.04 B(+16.1%) |
| Sep 2021 | - | -$3.64 B(-38.1%) | -$16.40 B(+5.3%) |
| Jun 2021 | - | -$5.88 B(+85.4%) | -$15.57 B(+27.0%) |
| Mar 2021 | - | -$3.17 B(-14.1%) | -$12.25 B(+6.5%) |
| Dec 2020 | -$11.50 B(-161.5%) | -$3.69 B(+31.3%) | -$11.50 B(-161.2%) |
| Sep 2020 | - | -$2.81 B(+9.5%) | $18.80 B(-11.2%) |
| Jun 2020 | - | -$2.57 B(+6.1%) | $21.17 B(-2.3%) |
| Mar 2020 | - | -$2.42 B(-109.1%) | $21.67 B(+15.8%) |
| Dec 2019 | $18.71 B(-230.0%) | $26.60 B(-6132.2%) | $18.71 B(-259.6%) |
| Sep 2019 | - | -$441.00 M(-78.7%) | -$11.72 B(+13.1%) |
| Jun 2019 | - | -$2.07 B(-61.5%) | -$10.36 B(-40.0%) |
| Mar 2019 | - | -$5.38 B(+40.7%) | -$17.27 B(+20.0%) |
| Dec 2018 | -$14.40 B(+161.2%) | -$3.83 B(-517.6%) | -$14.40 B(+15.2%) |
| Sep 2018 | - | $916.00 M(-110.2%) | -$12.50 B(-12.1%) |
| Jun 2018 | - | -$8.98 B(+257.8%) | -$14.22 B(+128.4%) |
| Mar 2018 | - | -$2.51 B(+30.1%) | -$6.23 B(+13.0%) |
| Dec 2017 | -$5.51 B | -$1.93 B(+138.0%) | -$5.51 B(-9.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | -$810.00 M(-17.3%) | -$6.09 B(-8.4%) |
| Jun 2017 | - | -$980.00 M(-45.4%) | -$6.65 B(+47.6%) |
| Mar 2017 | - | -$1.79 B(-28.3%) | -$4.50 B(+14.6%) |
| Dec 2016 | -$3.93 B(-168.3%) | -$2.50 B(+82.5%) | -$3.93 B(+1.8%) |
| Sep 2016 | - | -$1.37 B(-217.8%) | -$3.86 B(+8.9%) |
| Jun 2016 | - | $1.16 B(-195.5%) | -$3.54 B(-164.8%) |
| Mar 2016 | - | -$1.22 B(-49.9%) | $5.46 B(-5.0%) |
| Dec 2015 | $5.75 B(-274.7%) | -$2.43 B(+130.2%) | $5.75 B(-21.2%) |
| Sep 2015 | - | -$1.06 B(-110.4%) | $7.30 B(-4.4%) |
| Jun 2015 | - | $10.17 B(-1193.4%) | $7.64 B(-359.3%) |
| Mar 2015 | - | -$930.00 M(+5.4%) | -$2.95 B(-10.5%) |
| Dec 2014 | -$3.29 B(-4.3%) | -$882.00 M(+22.7%) | -$3.29 B(+4.3%) |
| Sep 2014 | - | -$719.00 M(+73.3%) | -$3.16 B(+3.5%) |
| Jun 2014 | - | -$415.00 M(-67.5%) | -$3.05 B(-2.7%) |
| Mar 2014 | - | -$1.28 B(+71.0%) | -$3.14 B(-8.9%) |
| Dec 2013 | -$3.44 B(-278.2%) | -$747.00 M(+21.9%) | -$3.44 B(+1024.8%) |
| Sep 2013 | - | -$613.00 M(+22.6%) | -$306.00 M(-112.0%) |
| Jun 2013 | - | -$500.00 M(-68.4%) | $2.55 B(+47.9%) |
| Mar 2013 | - | -$1.58 B(-166.2%) | $1.73 B(-10.7%) |
| Dec 2012 | $1.93 B(-128.5%) | $2.39 B(+6.5%) | $1.93 B(-195.6%) |
| Sep 2012 | - | $2.24 B(-269.2%) | -$2.02 B(-69.0%) |
| Jun 2012 | - | -$1.33 B(-3.6%) | -$6.51 B(-6.4%) |
| Mar 2012 | - | -$1.38 B(-11.9%) | -$6.96 B(+2.6%) |
| Dec 2011 | -$6.78 B(<-9900.0%) | -$1.56 B(-30.7%) | -$6.78 B(+29.9%) |
| Sep 2011 | - | -$2.25 B(+26.9%) | -$5.22 B(+75.8%) |
| Jun 2011 | - | -$1.77 B(+48.3%) | -$2.97 B(+148.3%) |
| Mar 2011 | - | -$1.20 B | -$1.20 B |
| Dec 2010 | $65.00 M(-101.3%) | - | - |
| Dec 2009 | -$4.88 B | - | - |
FAQ
- What is the all time high annual CFF for AbbVie?
- What is the all time high quarterly CFF for AbbVie?
- What is the all time high TTM CFF for AbbVie?
What is the all time high annual CFF for AbbVie?
AbbVie all-time high annual cash flow from financing activities is $18.71 B
What is the all time high quarterly CFF for AbbVie?
AbbVie all-time high quarterly cash flow from financing activities is $26.60 B
What is the all time high TTM CFF for AbbVie?
AbbVie all-time high TTM cash flow from financing activities is $21.67 B